Clinuvel Pharmaceuticals (ASX:CUV) — Material Events
ASX:CUV · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
CLINUVEL Stays the Course: CEO Retained as Vitiligo Program Takes Centre StageMedium
CLINUVEL Retains CEO Wolgen, Prioritizes Vitiligo Program, Eyes Nasdaq Listing in 2026
20 Mar 2026
·CEO Letter / Strategic Update
·85
Clinuvel Marks Ninth Year of Profit Growth Amid Vitiligo Clinical PushMedium
Clinuvel Reports Ninth Year of Revenue and Profit Growth, Declares Dividend
28 Aug 2025
·Preliminary Final Report
·85
Health Canada Grants Approval for CLINUVEL’s SCENESSE to Treat Rare EPP DisorderMedium
Health Canada approves SCENESSE® for EPP treatment, expanding CLINUVEL's market
13 July 2026
·Regulatory Approval
·85
CLINUVEL Secures EMA Nod for Pivotal Vitiligo Phase III Trial of SCENESSEMedium
CLINUVEL secures EMA scientific advice for pivotal Phase III vitiligo study with SCENESSE®
24 Apr 2026
·Regulatory Update
·85
Clinuvel Delivers Ninth Straight Profit with 10% Revenue Boost in FY2025Medium
Clinuvel Reports Strong FY2025 Financials with Revenue and Profit Growth, Declares Dividend
28 Aug 2025
·Annual Financial Results and Strategy Update
·85
EMA Greenlights Year-Round SCENESSE® for EPP, Lifting Dose CapsMedium
EMA approves year-round SCENESSE® treatment for EPP, removing dose limits
23 Sept 2025
·Regulatory Approval
·85
CLINUVEL Eyes Nasdaq Upgrade to Boost U.S. Market PresenceMedium
CLINUVEL to upgrade ADR program to Nasdaq Level II listing by end of 2025
22 Aug 2025
·ASX Announcement
·80
CLINUVEL Boosts Singapore Hub to Lead Next-Gen Peptide TherapiesMedium
CLINUVEL expands Singapore RD&I Centre to pioneer next-gen peptide therapies with five-year strategic investment
8 Dec 2025
·ASX Announcement
·75
FDA Drops Cardiac QT Study for SCENESSE, Citing Strong Safety DataMedium
FDA drops cardiac QT study requirement for SCENESSE®, confirming strong safety profile
27 Apr 2026
·Regulatory Update
·Unexpected
·75
Health Canada Extends SCENESSE® Review, Delaying EPP Treatment ApprovalMedium
Health Canada delays SCENESSE® approval for EPP, review extended to 2026
16 Oct 2025
·ASX Announcement
·Unexpected
·70
Clinuvel Advances Peptide Drug Delivery with VLRX-L Preclinical DosingMedium
Clinuvel starts preclinical dosing of novel controlled-release peptide platform VLRX-L, results due H2 2026
12 Jan 2026
·ASX Announcement
·70
CLINUVEL Unveils Promising Vitiligo Repigmentation Cases with SCENESSE®Medium
CLINUVEL presents positive vitiligo repigmentation case studies for SCENESSE® at EADV
19 Sept 2025
·ASX Announcement
·70
No articles in this tier for the last 12 months.
Market Mentions
5
- appeared in market wrap coverage
These are market wrap articles where Clinuvel Pharmaceuticals (ASX:CUV) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 25 (15 June -> 19 June) 2026
20 June 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Market Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026